Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
US11166936B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 6, 2020 |
| Grant date | Nov 9, 2021 |
| Priority date | — |
| Expiry date | Oct 6, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.